NX-5948
Sponsors
Nurix Therapeutics Inc., Nurix Therapeutics, Inc.
Conditions
B-cell LymphomaChronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia (CLL)Diffuse Large B Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Healthy VolunteerMantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)
Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingNCT05131022
Start: 2022-04-13End: 2028-01-01Target: 572Updated: 2026-07-02
Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948
CompletedNCT06691828
Start: 2024-11-01End: 2024-12-05Updated: 2025-03-12
A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers
CompletedNCT06717269
Start: 2024-11-30End: 2026-05-01Updated: 2026-07-28
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
RecruitingNCT07520006
Start: 2026-08-01End: 2033-05-01Target: 150Updated: 2026-08-28
Phase 2
A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton’s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)
RecruitingCTIS2025-521088-10-00
Start: 2025-10-23Target: 40Updated: 2025-10-06
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RecruitingNCT07221500
Start: 2025-10-15End: 2030-10-01Target: 100Updated: 2026-09-17